Short Interest in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Declines By 71.0%

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 208,100 shares, a decrease of 71.0% from the March 31st total of 718,800 shares. Based on an average trading volume of 3,490,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.6% of the shares of the stock are sold short.

NovaBay Pharmaceuticals Price Performance

Shares of NBY stock remained flat at $0.08 on Thursday. 491,539 shares of the stock were exchanged, compared to its average volume of 3,361,271. The company has a market capitalization of $324,170.00, a PE ratio of -0.01 and a beta of 2.82. NovaBay Pharmaceuticals has a 52-week low of $0.07 and a 52-week high of $1.42.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last posted its earnings results on Tuesday, March 26th. The biopharmaceutical company reported ($0.95) EPS for the quarter. The company had revenue of $3.73 million during the quarter. NovaBay Pharmaceuticals had a negative return on equity of 146.20% and a negative net margin of 79.70%. Sell-side analysts forecast that NovaBay Pharmaceuticals will post -2.54 EPS for the current fiscal year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.